Bioten Co., Ltd Logo

Bioten Co., Ltd

Develops biotech health supplements, animal feed additives, and functional cosmetics.

289170 | KO

Overview

Corporate Details

ISIN(s):
KR7289170003
LEI:
Country:
South Korea
Address:
전북특별자치도 정읍시 첨단2로 64 -, 정읍시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Bioten Co., Ltd. is a biotechnology company engaged in the development, manufacturing, and sale of health supplements, animal feed additives, and functional cosmetics. Established in 2011, the company focuses on commercializing scientific research and technology. Its product line includes health-functional foods such as probiotics, collagen, and a proprietary solubilized curcumin designed for enhanced absorption and immune support. The company also develops animal feed additives and explores therapeutic treatments through its drug pipeline research.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 00:00
Regulatory Filings
본점소재지변경
Korean 5.1 KB
2025-07-17 00:00
Regulatory Filings
[기재정정]신규시설투자등
Korean 13.2 KB
2025-06-26 00:00
Regulatory Filings
기업설명회(IR)개최결과
Korean 6.9 KB
2025-04-16 00:00
Regulatory Filings
신규시설투자등
Korean 7.9 KB
2025-03-26 00:00
AGM Information
정기주주총회결과
Korean 25.4 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.7 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 9.6 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 808.5 KB
2025-03-14 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.7 KB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 14.7 KB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 155.9 KB
2025-02-18 00:00
M&A Activity
주요사항보고서(유형자산양도결정)
Korean 15.2 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2024-11-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 74.5 KB
2024-11-19 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.4 KB

Automate Your Workflow. Get a real-time feed of all Bioten Co., Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Bioten Co., Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Bioten Co., Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Epitomee Medical Ltd. Logo
Develops ingestible therapeutic devices for weight management and targeted drug delivery.
Israel
EPIT
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France
ERYP
Esperion Therapeutics, Inc. Logo
Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.
United States of America
ESPR

Talk to a Data Expert

Have a question? We'll get back to you promptly.